Celgene reports updated data from 'MAGNIFY' study of Revlimid
Celgene announced results from an interim analysis of MAGNIFY, a phase IIIb study of REVLIMID plus rituximab combination therapy in patients with relapsed or refractory marginal zone lymphoma. Results were presented at the International Conference on Malignant Lymphoma, and expanded upon data presented earlier in the month at the American Society of Clinical Oncology meeting. At ASCO, interim data were presented from an analysis of a subset of patients from the MAGNIFY study with relapsed or refractory FL with early relapse and double-refractory disease. Data being presented at ICML in a separate analysis focused on patients with MZL, including nodal MZL, splenic MZL and mucosa-associated lymphoid tissue lymphoma. At a median follow-up of 13.8 months from initiation of therapy with the R2 combination, evaluable patients with MZL achieved an ORR of 66% with a CR/CRu rate of 44%. Evaluable nodal MZL patients had an ORR of 57% with a CR/CRu rate of 57%. Evaluable splenic MZL patients had an ORR of 63% with a CR of 25%; and evaluable MALT patients had an ORR of 80% with a CR/CRu rate of 40%. Median duration of response was not reached for any group. The most common grade 3 or 4 adverse events observed in patients with MZL were neutropenia, thrombocytopenia and leukopenia.